SCHEMBL4866426

SCHEMBL4866426

Cn1cc(-c2c([N+](=O)[O-])c(=O)n(Cc3ccccc3F)c(=O)n2Cc2ccccc2F)cn1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.46
L3MBTL1 Q9Y468 1/20 0.45
TSHR P16473 2/20 0.44
NPC1 O15118 1/20 0.44
LMNA P02545 2/20 0.43
KDM4E B2RXH2 1/20 0.43
MAPK1 P28482 1/20 0.43
HTT P42858 1/20 0.43
HSD17B10 Q99714 1/20 0.43
ADORA2A P29274 1/20 0.42
ADORA2B P29275 1/20 0.42
ADORA1 P30542 1/20 0.42
HPGD P15428 1/20 0.41
PKM P14618 1/20 0.40
PKLR P30613 1/20 0.40
CHRM1 P11229 7/20 0.40
PDE1A P54750 1/20 0.40
PDE1B Q01064 1/20 0.40
PDE1C Q14123 1/20 0.40
CHRM5 P08912 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4862734 0.90 MAPT (0.44) ALDH1A1L3MBTL1TSHRNPC1ADORA2A
SCHEMBL4864902 0.88 ADORA2B (0.49) ALDH1A1L3MBTL1TSHRNPC1LMNA
SCHEMBL4862897 0.86 ALDH1A1 (0.44) ALDH1A1L3MBTL1TSHRNPC1LMNA
SCHEMBL4861931 0.83 ADORA2B (0.51) ALDH1A1L3MBTL1ADORA2AADORA2BADORA1
SCHEMBL4860861 0.82 ADORA2B (0.59) ADORA2AADORA2BADORA1
SCHEMBL4916169 0.82 ADORA2B (0.48) ALDH1A1L3MBTL1TSHRNPC1LMNA
SCHEMBL4858904 0.82 ADORA2B (0.48) ALDH1A1L3MBTL1TSHRLMNAADORA2A
SCHEMBL4866175 0.82 ADORA2B (0.54) ALDH1A1L3MBTL1ADORA2AADORA2BADORA1
SCHEMBL4762425 0.81 ALDH1A1 (0.39) ALDH1A1L3MBTL1TSHRNPC1LMNA
SCHEMBL4861944 0.81 ADORA2B (0.47) ALDH1A1L3MBTL1ADORA2AADORA2BADORA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7449473-B2 Substituted pyrrolo[3,2-d]pyrimidin-2,4-diones as A2b adenosine receptor antagonists CV THERAPEUTICS, INC. (US) 2008-11-11 US disclosed
US-20050119287-A1 A2B adenosine receptor antagonists GILEAD PALO ALTO, INC. 2005-06-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050119287-A1 A2B adenosine receptor antagonists ADORA2B, ADORA2A, ADORA3 ALDH1A1 1178/4885L3MBTL1 2622/4885TSHR 351/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.